Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
OXFORD, England - Exscientia, a leading artificial intelligence (AI) driven biopharmaceutical company, has recently announced its acquisition of GT Apeiron’s share of the oral CDK7 inhibitor programme. This strategic move grants Exscientia complete control over GTAEXS617 (617), a promising compound with potential best-in-class features. The acquisition also includes all related intellectual property, further strengthening Exscientia’s drug discovery portfolio.
The CDK7 (Cyclin-Dependent Kinase 7) enzyme plays a crucial role in regulating cell division and transcription. Inhibiting CDK7 has emerged as a promising approach for designing new cancer therapeutics. 617, a novel oral CDK7 inhibitor, has shown significant potential in preclinical studies and is currently undergoing a monotherapy dose escalation phase in the ELUCIDATE clinical trial. This phase aims to evaluate the compound’s safety, pharmacokinetics (how the drug is processed in the body), and pharmacodynamics (how the drug affects the body) in patients with advanced solid tumors.
As the recruitment process for the ELUCIDATE trial progresses well, Exscientia’s acquisition of GT Apeiron’s share will enable them to have full control over the development and commercialization of 617. This move aligns with Exscientia’s commitment to leveraging AI and cutting-edge technologies to expedite the drug discovery process and deliver innovative treatments to patients.
Dr. Andrew Hopkins, CEO of Exscientia, expressed his excitement about the acquisition, stating, Gaining full control of 617 is a crucial step in our mission to accelerate the delivery of breakthrough therapies to patients in need. He further added that the acquisition strengthens Exscientia’s position as a leader in AI-driven drug discovery.
The data readout from the monotherapy dose escalation phase of the ELUCIDATE trial is eagerly anticipated. This milestone will provide valuable insights into the safety and efficacy of 617, further informing its clinical development. Exscientia’s AI-driven approach has significantly shortened the traditional drug discovery timeline, enabling faster translation from preclinical studies to clinical trials. By combining computational algorithms and machine learning models, Exscientia’s platform can rapidly generate and prioritize lead compounds, expediting the identification of potential best-in-class therapeutics.
The acquisition of GT Apeiron’s share of the CDK7 inhibitor programme signifies another successful venture for Exscientia as it continues to expand its portfolio of innovative drug candidates. With the potential to become a best-in-class CDK7 inhibitor, 617 holds promise for patients in dire need of effective treatments for advanced solid tumors.
In conclusion, Exscientia’s acquisition of GT Apeiron’s share of the oral CDK7 inhibitor programme has positioned the company at the forefront of the race to develop breakthrough cancer therapeutics. By gaining full control of GTAEXS617 and associated intellectual property, Exscientia is poised to drive the clinical development and expedite the potential commercialization of this promising compound. The completion of the ELUCIDATE trial’s monotherapy dose escalation phase will provide crucial data, further solidifying 617’s potential as a best-in-class CDK7 inhibitor. As Exscientia continues to pioneer AI-driven drug discovery, patients can look forward to innovative treatments arising from the fusion of cutting-edge technologies and human ingenuity.
Comments